Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pycnogenol in ADHD
NCT02700685Phase 3Completed
- Start
- Sep 2017
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) (3 arms). Primary endpoint: Summed ADHD score of the ADHD-Rating Scale as rated by teachers at 10 weeks. Started Sep 2017; status: completed.
02
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02700685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700685.